TLX is a $1.5bn biotech which has been under significant pressure since it reported for the December quarter primarily because cash reserves had more than halved to just over $22m. The news that it had received regulatory approval for its lead prostate cancer imaging product illuccix is clearly now regarded as old news and its all about commercialisation – the co-founders selling over 8% of their holding in the business hasn’t helped market confidence.
scroll
Performance update for March, stocks that drove returns & our current positioning
Close
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
MM is neutral TLX
Add To Hit List
Related Q&A
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.